Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials

Venous thromboembolism (VTE) is a common cause of morbidity and mortality in cancer patients. Until recently, guidelines recommended the use of low-molecular weight heparin (LMWH) as standard of care for VTE in patients with cancer. Despite the proven efficacy of direct oral anticoagulants (DOACs) f...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Heart, lung & circulation lung & circulation, 2022-05, Vol.31 (5), p.716-725
Hauptverfasser:	Murphy, Alexandra C., Koshy, Anoop N., Farouque, Omar, Yeo, Belinda, Raman, Jaishankar, Kearney, Leighton, Yudi, Matias B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticoagulation Cancer Cardio-oncology Direct oral anticoagulation Factor Xa inhibitor Low molecular weight heparin Venous thromboembolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!